Ovid Therapeutics (OVID) Net Cash Flow (2016 - 2026)

Ovid Therapeutics' Net Cash Flow history runs 11 years deep, the most recent figure standing at $81.0 million for Q1 2026.

• Quarterly Net Cash Flow rose 1668.89% year-over-year to $81.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $73.3 million (up 860.26% YoY) and the FY2025 annual result came in at -$12.9 million, down 1649.59% from the prior year.
• Net Cash Flow was $81.0 million for Q1 2026 at Ovid Therapeutics, up from -$7.3 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $81.0 million in Q1 2026 and bottomed at -$93.9 million in Q2 2022.
• A 5-year average of -$5.5 million and a median of -$7.3 million in 2025 frame the typical range for Net Cash Flow.
• Annual changes were most pronounced in 2022 — Net Cash Flow plunged 349.4% — and 2026, when it soared 1668.89%.
• Ovid Therapeutics' Net Cash Flow stood at -$13.4 million in 2022, then plunged by 127.01% to -$30.4 million in 2023, then jumped by 137.13% to $11.3 million in 2024, then tumbled by 164.31% to -$7.3 million in 2025, then surged by 1216.62% to $81.0 million in 2026.
• Business Quant data shows OVID's Net Cash Flow at $81.0 million in Q1 2026, -$7.3 million in Q4 2025, and -$7.8 million in Q3 2025.